Incorporated in 1977, Mangalam Drugs& Organics Ltd manufactures Active Pharmaceutical Ingredients andIntermediates[1]
Business Overview:[1]Company manufactures bulk drugs, organic and inorganic chemicals. It is among the few companies which are World Health Organization -approved Indian companies to be associated with the William J Clinton Foundation for manufacture of anti-malarial drugs. Company supplies artemisinin-based bulk drugs to pharmaceutical companies, for manufacturing anti-malarial formulations
| S.No. | Name | Current Price (Rs.) | Price to Earning | Market Capitalization (Rs.Cr.) | Dividend yield (%) | Net Profit latest quarter (Rs.Cr.) | YOY Quarterly profit growth (%) | Sales latest quarter (Rs.Cr.) | YOY Quarterly sales growth (%) | Return on capital employed (%) | Sales (Rs.Cr.) | OPM (%) | Profit after tax (Rs.Cr.) | Profit after tax latest quarter (Rs.Cr.) | Price to book value | Return on assets (%) | Debt to equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Sun Pharma.Inds. | 1782.60 | 37.05 | 427717.60 | 0.90 | 3124.95 | 2.56 | 14478.31 | 8.93 | 20.21 | 54964.01 | 30.12 | 11543.96 | 3117.95 | 5.50 | 12.97 | 0.07 |
| 2. | Divi's Lab. | 6642.50 | 70.94 | 176292.38 | 0.45 | 689.00 | 35.10 | 2715.00 | 16.12 | 20.44 | 10029.00 | 32.37 | 2485.00 | 689.00 | 11.44 | 13.53 | 0.01 |
| 3. | Torrent Pharma. | 4092.20 | 63.93 | 138496.88 | 0.78 | 591.00 | 32.49 | 3302.00 | 14.30 | 27.05 | 12248.00 | 32.60 | 2166.53 | 600.17 | 16.39 | 13.26 | 0.33 |
| 4. | Cipla | 1467.90 | 21.80 | 118607.61 | 0.89 | 1353.37 | 3.73 | 7589.44 | 7.64 | 22.72 | 28349.57 | 25.40 | 5441.14 | 1351.17 | 3.60 | 14.72 | 0.01 |
| 5. | Dr Reddy's Labs | 1242.80 | 17.97 | 103748.51 | 0.64 | 1336.80 | 7.28 | 8828.30 | 9.83 | 22.69 | 34310.00 | 24.64 | 5772.20 | 1347.10 | 2.88 | 12.95 | 0.16 |
| 6. | Lupin | 2214.30 | 23.36 | 101043.20 | 0.54 | 1484.83 | 73.34 | 7047.51 | 24.23 | 21.30 | 24750.69 | 27.25 | 4324.63 | 1477.92 | 5.15 | 12.41 | 0.32 |
| 7. | Mankind Pharma | 2311.80 | 54.55 | 95387.58 | 0.04 | 520.18 | -22.00 | 3697.16 | 20.77 | 15.98 | 13545.67 | 24.12 | 1748.55 | 511.51 | 6.24 | 8.89 | 0.55 |
| 8. | Mangalam Drugs | 35.09 | – | 55.39 | 0.00 | -7.25 | -369.52 | 49.54 | -38.03 | 8.03 | 268.64 | 4.31 | -19.43 | -7.25 | 0.44 | 1.92 | 0.74 |
| – | Median: 150 Co. | 409.67 | 30.81 | 1757.37 | 0.11 | 13.03 | 12.32 | 157.2 | 10.84 | 14.98 | 582.87 | 15.96 | 44.55 | 13.73 | 3.15 | 8.6 | 0.22 |
Standalone figures in ₹ crores
| Dec 2022 | Dec 2023 | Dec 2024 | Jun 2023 | Jun 2024 | Jun 2025 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 63.32 | 97.34 | 88.71 | 87.46 | 76.53 | 57.35 | 91.11 | 102.24 | 73.04 | 108.33 | 81.56 | 79.94 | 49.54 |
Expenses | 56.84 | 90.36 | 79.94 | 90.94 | 68.34 | 61.86 | 90.87 | 90.54 | 62.88 | 99.89 | 79.37 | 71.25 | 52.37 |
Operating Profit | 6.48 | 6.98 | 8.77 | -3.48 | 8.19 | -4.51 | 0.24 | 11.70 | 10.16 | 8.44 | 2.19 | 8.69 | -2.83 |
Other Income | 0.13 | -0.00 | 0.13 | 0.02 | 0.02 | -0.00 | 0.29 | 0.05 | 0.21 | -0.00 | 0.03 | 0.14 | 0.03 |
Profit before tax | 0.51 | 0.05 | 1.48 | -10.29 | 0.59 | -12.93 | -5.65 | 3.94 | 1.73 | 3.12 | -4.75 | 1.19 | -12.36 |
Tax % | 15.69% | -920.00% | 5.41% | -7.29% | -355.93% | 6.19% | -22.30% | 9.90% | 90.75% | 28.85% | -25.05% | -125.21% | -41.42% |
Net Profit | 0.43 | 0.50 | 1.40 | -9.54 | 2.68 | -13.73 | -4.39 | 3.55 | 0.15 | 2.23 | -3.56 | 2.69 | -7.25 |
EPS in Rs | 0.27 | 0.32 | 0.88 | -6.03 | 1.69 | -8.67 | -2.77 | 2.24 | 0.09 | 1.41 | -2.25 | 1.70 | -4.58 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 123 | 221 | 295 | 299 | 269 | 228 | 282 | 380 | 451 | 372 | 369 | 318 | 269 |
Expenses | 113 | 200 | 257 | 252 | 222 | 218 | 259 | 327 | 402 | 347 | 351 | 282 | 257 |
Operating Profit | 10 | 20 | 38 | 47 | 47 | 10 | 24 | 53 | 49 | 26 | 17 | 36 | 12 |
Other Income | 0 | 0 | 0 | -0 | 1 | 0 | 1 | 5 | 0 | 0 | 0 | 0 | 0 |
Interest | 10 | 10 | 9 | 10 | 12 | 9 | 10 | 9 | 11 | 13 | 14 | 15 | 17 |
Depreciation | 4 | 4 | 4 | 5 | 7 | 7 | 8 | 9 | 10 | 11 | 15 | 16 | 17 |
Profit before tax | -4 | 6 | 24 | 31 | 29 | -6 | 6 | 40 | 28 | 2 | -11 | 5 | -22 |
Net Profit | -3 | 6 | 16 | 22 | 20 | -8 | 8 | 28 | 20 | 1 | -9 | 7 | -19 |
EPS in Rs | -2.31 | 4.66 | 11.15 | 14.08 | 12.57 | -5.07 | 5.21 | 17.67 | 12.42 | 0.80 | -5.72 | 4.37 | -12.28 |
Dividend Payout % | 0% | 0% | 0% | 0% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | – |
Standalone figures in ₹ crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 13 | 13 | 14 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
Reserves | 10 | 16 | 47 | 70 | 88 | 80 | 88 | 115 | 135 | 136 | 127 | 133 | 112 |
Borrowings | 77 | 78 | 60 | 66 | 69 | 65 | 52 | 70 | 88 | 89 | 107 | 96 | 95 |
Other Liabilities | 25 | 63 | 38 | 38 | 54 | 50 | 75 | 64 | 90 | 117 | 108 | 114 | 87 |
Total Liabilities | 125 | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 | 310 |
Fixed Assets | 53 | 53 | 54 | 93 | 102 | 103 | 101 | 118 | 135 | 142 | 147 | 156 | 152 |
Gross Block | 88.28 | 91.82 | 97.57 | 140.26 | 156.14 | 165.15 | 170.92 | 196.69 | 220.30 | 236.91 | 254.50 | 276.70 | – |
Accumulated Depreciation | 34.89 | 38.88 | 43.38 | 47.70 | 54.23 | 61.66 | 69.85 | 78.88 | 85.34 | 94.54 | 107.20 | 121.18 | – |
CWIP | 0 | 0 | 5 | 0 | 0 | 0 | 1 | 6 | 6 | 9 | 8 | 3 | 4 |
Investments | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Assets | 72 | 117 | 100 | 95 | 125 | 107 | 128 | 140 | 188 | 206 | 202 | 201 | 155 |
Total Assets | 125 | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 | 310 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operating Activity | 7 | 14 | 22 | 43 | 25 | 22 | 31 | 28 | 26 | 38 | 12 | 43 |
Cash from Investing Activity | -2 | -4 | -11 | -39 | -16 | -9 | -7 | -31 | -27 | -22 | -18 | -19 |
Cash from Financing Activity | -5 | -10 | -11 | -3 | -9 | -11 | -23 | 3 | 3 | -17 | 6 | -22 |
Net Cash Flow | 0 | 1 | -0 | 0 | -0 | 1 | 0 | -1 | 1 | -1 | -0 | 2 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 88 | 73 | 37 | 45 | 61 | 28 | 52 | 52 | 38 | 46 | 28 | 45 |
Inventory Days | 170 | 134 | 85 | 69 | 132 | 175 | 121 | 85 | 139 | 200 | 185 | 303 |
Days Payable | 97 | 128 | 37 | 38 | 82 | 77 | 106 | 63 | 65 | 139 | 124 | 199 |
Cash Conversion Cycle | 161 | 79 | 85 | 75 | 111 | 126 | 67 | 74 | 112 | 107 | 88 | 148 |
Working Capital Days | 29 | 26 | 32 | 19 | 31 | 21 | 10 | 23 | 43 | 38 | 18 | 13 |
ROCE % | 6% | 16% | 29% | 31% | 25% | 2% | 11% | 27% | 18% | 6% | 1% | 8% |
Direct from BSE filings, auto-summarised
External media mentions & references
Editorial & research coverage
Stock Analysis
Mangalam Drugs & Organics Ltd is an Indian pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates, with a focus on bulk drugs.
Currently no data available for Key Growth Triggers.
Currently no data available for Order Book.
The resignation of Independent Director Shri Rukmesh P. Dhandhania, effective January 16, 2026, attributed to personal reasons, occurs amidst a backdrop of the company's recent financial struggles including net losses and a modified audit opinion on deferred tax assets in earlier quarters, alongside previous management changes (CFO, CS resignations).
Shri Rukmesh P. Dhandhania's resignation is effective from January 16, 2026.
Corporate Announcements
